The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study
Journal of Gastroenterology · 2026-11 · 61 (11) · 1643-1652
DOI: 10.1007/s00535-026-02449-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, online erschienen am 15.06.2026. Verfasst von Bregje Mol und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Cholangitis, Sclerosing, Cholagogues and Choleretics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
Background
Although ursodeoxycholic acid (UDCA) is commonly prescribed for primary sclerosing cholangitis (PSC), a beneficial long-term effect on solid clinical endpoints has not yet been established. This study evaluated the efficacy of UDCA on long-term transplant-free survival in a longitudinal population-based cohort.
Methods
We conducted a retro/prospective study between January 2008 and August 2020, using data from the Dutch population-based EpiPSC2 cohort. Medication use was collected through medical chart review, periodic questionnaires, and the national pharmacy prescription database. The effect of UDCA use was assessed as time-dependent variable using a Cox proportional hazards model. Sex, age at diagnosis, PSC type, IBD status, transplant center inclusion, and PSC diagnosis year were considered as covariates.
Results
Medication data were available for 739 cases. Individuals with uncertain use of UDCA were excluded, resulting in a study population of 527. No discernable effect of UDCA use was observed on the endpoints liver transplantation (LT)/all-cause mortality [adjusted HR 1.13 (95%CI 0.76–1.67)] nor LT/PSC-related death/occurrence of hepatobiliary malignancy [adjusted HR 1.07 (95%CI 0.71–1.60)]. The HR of UDCA use was numerically reduced for hepatobiliary malignancy [0.68 (95%CI 0.34–1.37)].
Conclusion
Our study failed to demonstrate that UDCA use impacts long-term outcomes in patients with PSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Amsterdam, The Netherlands.
- Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands.
- Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
- Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.
Förderung
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
Zitieren
APA
Mol, B., van Munster, K., Weersma, R., Inderson, A., Boonstra, K., Drenth, J., van Meer, S., de Vries, E., Spanier, M., Vrij, A., Verlaan, T., van Duijn, F., Ponsioen, W., Dijkgraaf, M., Ponsioen, C., & EpiPSC2 study group (2026). The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study. Journal of Gastroenterology, 61(11), 1643-1652. https://doi.org/10.1007/s00535-026-02449-7
Vancouver
Mol B, van Munster K, Weersma R, Inderson A, Boonstra K, Drenth J, et al. The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study. Journal of Gastroenterology. 2026;61(11):1643-1652. doi:10.1007/s00535-026-02449-7
BibTeX
@article{Mol2026,
author = {Mol, Bregje and van Munster, Kim and Weersma, Rinse and Inderson, Akin and Boonstra, Kirsten and Drenth, Joost and van Meer, Suzanne and de Vries, Elsemieke and Spanier, Marcel and Vrij, Anton and Verlaan, Tessa and van Duijn, Femke and Ponsioen, Willemijn and Dijkgraaf, Marcel and Ponsioen, Cyriel and EpiPSC2 study group, EpiPSC2 study group},
title = {The longstanding issue of the benefit of ursodeoxycholic acid in primary sclerosing cholangitis: a long-term population-based study},
journal = {Journal of Gastroenterology},
year = {2026},
volume = {61},
number = {11},
pages = {1643--1652},
doi = {10.1007/s00535-026-02449-7}
}
EUVIMED